

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Form PTO-1449 (Modified) (Use several sheets if necessary)

	PLETE IF KN	10WN # 11
Application Number	υ9/772,109	*****
Confirmation Number	8965	
Filing Date	January 26, 2001	RECEIVE
First Named Inventor	Allan S. Lau	THE OF IAT
Group Art Unit	1648	JAN 2 8 2003
Examiner Name	Ulrike Winkler	2003
Attorney Docket No.	54099-8003.US01	TECH CENTER 1600/0

Shee	et <u> </u>	1 1		of		3	Attomey Docket No.	54099-8003.US0	1 TECH CENTER	1600/
		·	<del></del>	<del></del>	-	U.S. DATENT	DOCUMENTS.			
Examiner Initials	1 .	U.		or Applicati Kind (if kr		Name of Pa	tentee or Inventor	Date of Publication or Filing Date of Cited Document	Pages, Columns, Line Where Relevant Figures Appear	es,
W		6,159,71		<del></del>		Allen S. Lau	<del></del>	11/19/1999	, <u>Ş</u>	
W		US 2	2001/003	31859 A1		Lau et al.	·	10/18/2001		
					FC	DREIGN PATE	NT DOCUMENTS			
Examiner Initial	Cite No.		eign Pate		ation nd Cod f known		atentee or Applicant ted Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	т
W		WO	00/7	7236 A2	2	Genetrol Bio	otherapeutics, Inc.	06/14/00		$T \cap$
1		wo	01/1	8185 A1		Genetrol Bio	otherapeutics, Inc.	09/08/00		
		wo	02/05	59281 A2		Genetrol Bio	otherapeutics, Inc.	01/25/02		$\Box$
		wo.	02/2	2848 A2		Genetrol Bio	otherapeutics, Inc.	09/11/01		
		wo	97/0	8292 A		University	of California	03/06/97		
·		wo	98/0	0013 <sub>.</sub> A		University	of California	01/08/98		$\Box$
V		WO	97/0	8324 A		University	of California	03/06/97		$\prod$
		Interr	nationa	l Searc	n Rep	oort from PC	T/US02/02297, fi	led 01/25/200	02	
							NT LITERATURE D			<del></del>
Examiner Initials	Cite No.	(t	Include book, mag	e name of the	e autho al, seria	al, symposium, cata	TERS), title of the article alog, etc.), date, page(s), ountry where published.	(when appropriate) volume issue numb	, title of the item per(s), publisher, city	Т
he		Prote Europ	Balachandran, S., et al., XP002159409, "Activation of the dsRNA-dependent Protein Kinase, PKR, Induces Apoptosis through FADD-mediated Death Signaling," <i>European Molecular Biology Organization Journal</i> , 17:23 6888-6902 (1998), Abstract Only.							
			Chittenden, T., et al., XP002910967, "Induction of Apoptosis by the BCL-2 Homologue Bak," <i>Nature</i> , 374:20 733-736 (1995).							
4		Inhibi	Derwent, XP-002170158, "Efficient Production of Useful Substances Under Inhibition by Apoptosis – by Transforming an Apoptosis-Suppressive Gene into Host Inimal Cell," Abstract Only.							

La	1	
EXAMINER / //	. 11.	DATE CONSIDERED
// /		10/7/03
*EXAMINER: In	nitial if reference considered, whether or not criteria is in confor	mance with MPEP 609. Draw line through citation if not in conformance and not
co	onsidered. Include copy of this form with next communication t	o application(s).

6	P = VCg
	AN 2 7 2003
1	ENT HOOTHE

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Form PTO-1449 (Modified) (Use several sheets if necessary)

(	PLETE IF KN	OWN	
Application Number	υ9/772,109		
Confirmation Number	8965		
Filing Date	January 26, 2001	DEOENE	
First Named Inventor	Allan S. Lau	KEUEIVE	<u>:</u> L
Group Art Unit	1648		
Examiner Name	Ulrike Winkler	JAN 2 8 200	j
Attorney Docket No.	54099-8003.US01	TENL OF ITED 4000	100

of 3 Attorney Docket No. 54099-8003.US01 TECH CENTER 1600/290

·				U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.			Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear			
		· · · · · · · · · · · · · · · · · · ·		RT-NON PATENT LITERATURE D	<del></del>				
Examiner Initials	Cite.			or (in CAPITAL LETTERS), title of the article rial, symposium, catalog, etc.), date, page(s), and/or country where published.			Т		
W		Donze, O., et al., "Regulatable Expression of the Interferon-Induced Double-Stranded RNA Protein Kinase PKR Induces Apoptosis and Fas Receptor Expression," <i>Virology</i> , 256: 322-329 (1999).							
		Enhanced Tra	Fujita, T., et al., "Overexpression of BCL-2 Improved Survival of COS-1 Cells and Enhanced Transient Protein Production," <i>Journal of Fermentation and Bioengineering</i> , 82:6 589-591 (1996).						
		Garland, J., et al., XP002159411, "Energy Metabolism during Apoptosis: BCL-2 Promotes Survival in Hematopoietic Cells Induced to Apoptose by Growth Factor Withdrawal by Stabilizing a Form of Metabolic Arrest," <i>Journal of Biological Chemistry</i> , 272:8 4680-4688 (1997).							
		Dependent P Translation Ir	Gil, J. et al., XP002159410, "Induction of Apoptosis by Double-Stranded-RNA-Dependent Protein Kinase (PKR) Involves the Alpha Subunit of Eukaryotic Translation Initiation Factor 2 and NF-kappaB," <i>Molecular and Cellular Biology</i> , 19:7 4653-4663 (1999), Abstract Only.						
		Containing P	Han, D.K.M., et al., XP002071904, "MRIT, A Novel Death-Effector Domain-Containing Protein, Interacts with Caspases and BCLXL and Initiates Cell Death,"  Proceedings of the National Academy of Sciences of USA, 94:21 11333-11338						
b	*4	Interacts with	the BCL2 Amyloid Be	02156341, "The Cell Death-Pr Family, is Induced During Ned eta Protein," <i>Journal of Biologi</i>	uronal Apopto	osis Following			
<del></del>									

EXAMINER	ller h	Ju	DATE CONSIDERED	10/7/03
*EXAMINER:		lered, whether or not criteria i y of this form with next comm		Draw line through citation if not in conformance and not

PE	No. of the last			•	( 'IPLETE IF KNOWN				
	/ L - 10%/			•	Application Number	1 v9/772,109			
/c		INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Confirmation Number	8965			
$\setminus$	JAN 2 7 2003	-3			Filing Date	January 26, 2001	RECEIVE		
	<u> </u>	,	449 (Modified)		First Named Inventor	Allan S. Lau	LIVEL		
		(Use several she	ets if necessary	y)	Group Art Unit	1648	JAN 2 8 2002		
	STENT & TROUTER		·		Examiner Name	Ulrike Winkler			
	Sheet	3	of	3	Attorney Docket No.	54099-8003.US01	TECH CENTER 1600/000		
				· · · ·		•	<del></del>		

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	Т
W		Ossina, N., et al., XP-008007767, "Exogenous PKR Expression in Apoptosis-Resistant CRMA Transfected Mammalian Cells," <i>Journal of Interferon and Cytokine Research</i> , 24:1 102-103 (2001). Abstract Only	
		Srivastava, S.P., et al., "Phosphorylation of Eukaryotic Translation Initiation Factor 2 Mediates Apoptis in Response to Activation of the Double-stranded RNA-dependent Protein Kinase," <i>The Journal of Biological Chemistry</i> , 278:4 2416-2423 (1998).	
		Yeung, M.C., et al., "An essential role for the interferon-inducible, double-stranded RNA-activated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells," <i>Proc. Natl. Acad. Sci. USA</i> , 93: 12451-12455 (1996).	
<b>V</b>		Yeung, M.C., et al., "Tumor Suppressor p53 as a Component of the Tumor Necrosis Factor-induced, Protein Kinase PKR-mediated Apoptotic Pathway in Human Promonocytic U937 Cells," <i>The Journal of Biological Chemistry</i> , 273:39 25198-25202 (1998).	

EXAMINER White White

DATE CONSIDERED

10/7/03

\*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).